Clinical trials: Tamoxifen
Depressive Syndrome
Osteoporosis Treatment in Post-menopausal Women
The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.
- Trial name
- NCT03006003
- Testing
- Raloxifene, Alendronate
- Where
- 2 sites in Taiwan
- Volunteers
- 500 people
- Sponsor
- Taichung Veterans General Hospital
Breast Cancer
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen.
- Trial name
- TEXT (NCT00066703)
- Testing
- exemestane, tamoxifen, triptorelin
- Where
- 228 sites in United States, Australia and 15 more
- Volunteers
- 2,672 people
- Sponsor
- ETOP IBCSG Partners Foundation
Menopause
Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer
The purpose of this study is to determine the effects of a personalized menopausal therapy risk assessment and genetic counseling intervention on knowledge, risk perception, and decision-making in healthy women at increased risk…
- Trial name
- NCT00349011
- Testing
- Personalized risk assessment, genetic counseling intervention
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yale University
Breast Cancer
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer
The present study is a randomized open-label -phase III study that aims to compare the efficacy and safety of the adjuvant chemotherapy with simultaneous or sequential application of Zoladex up to 2-3 years for ≤ 45 year old…
- Trial name
- NCT01712893
- Testing
- Zoladex
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Fudan University
Breast Atypical Hyperplasia, Breast Carcinoma
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05941520
- Testing
- Acolbifene Hydrochloride, Biospecimen Collection, Mammography
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Male Breast Cancer, Stage II Breast Cancer
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
This phase II trial is studying how well giving bevacizumab together with combination chemotherapy works in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes.
- Conditions
- Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00119262
- Testing
- doxorubicin hydrochloride, cyclophosphamide, bevacizumab
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- National Cancer Institute (NCI)
Post Menopausal Women With Early Breast Cancer
Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)
Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire. Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).
- Trial name
- FAST (NCT01050634)
- Testing
- Aromasin (exemestane)
- Volunteers
- 980 people
- Sponsor
- Pfizer
Breast Cancer
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
This randomized, multicenter, 2-arm, open-label study (TH3RESA) will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's choice in participants with metastatic or…
- Trial name
- TH3RESA (NCT01419197)
- Testing
- Trastuzumab emtansine, Treatment of physician's choice
- Where
- 184 sites in United States, Australia and 20 more
- Volunteers
- 602 people
- Sponsor
- Hoffmann-La Roche
Gynaecomastia, Prostate Cancer
Casodex - Nolvadex Combination
This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex.
- Trial name
- NCT00637871
- Testing
- Casodex, Tamoxifen
- Sponsor
- AstraZeneca
Intraocular Melanoma
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00489944
- Testing
- cisplatin, sunitinib malate, tamoxifen citrate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status.
- Conditions
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer
- Trial name
- NCT06348134
- Testing
- Trastuzumab emtansine, Pertuzumab Injection, Docetaxel
- Where
- 4 sites in Nigeria
- Volunteers
- 74 people
- Sponsor
- University of Chicago
Breast Neoplasms
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.
- Trial name
- NCT00034125
- Testing
- LY353381, tamoxifen
- Where
- 11 sites in United States, Argentina and 3 more
- Sponsor
- Eli Lilly and Company
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
This is a phase II, randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs.
- Trial name
- NCT06917313
- Testing
- Fezolinetant
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yale University
Breast Cancer
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells.
- Trial name
- NCT00003906
- Testing
- Raloxifene, Tamoxifen
- Where
- 516 sites in United States, Canada and 1 more
- Volunteers
- 19,747 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
This is a biomedical study of interventional type which includes 29 patients on 9 months: 8 months recruiting and 1 month follow up.
- Trial name
- OXYTAM (NCT01553903)
- Testing
- Tamoxifen,, Exemestane, Anastrozole
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Institut Claudius Regaud
Brain and Central Nervous System Tumors
Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as tamoxifen may make the tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00006388
- Testing
- tamoxifen citrate, radiation therapy
- Where
- 257 sites in United States, Canada
- Volunteers
- 77 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells following…
- Trial name
- NCT00047099
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- 2 sites in Germany
- Volunteers
- 446 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Breast Cancer Female
Factors Influencing Tamoxifen Adherence in Women With Breast Cancer Receiving Tamoxifen in Botswana.
Botswana is an ideal location to investigate tamoxifen adherence for numerous reasons. First, in contrast to many other countries in SSA, tamoxifen is affordable and widely available to women with ER+ breast cancer in Botswana.
- Trial name
- TAM (NCT06660030)
- Testing
- No intervention
- Where
- Botswana
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Breast Cancer
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen
Aim of work: 1. To estimate the frequency of Cyp2D6*1 and *4 alleles in Egyptian patients maintained on tamoxifen (20 mg/day) for management of ER +ve breast cancer. 2.
- Trial name
- NCT03582865
- Testing
- Tamoxifen 20 mg
- Volunteers
- 100 people
- Sponsor
- Assiut University
Breast Cancer
ATAC - Arimidex, Tamoxifen Alone or in Combination
The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.
- Trial name
- NCT00849030
- Testing
- Anastozole (Arimidex), Tamoxifen (Nolvadex)
- Volunteers
- 9,358 people
- Sponsor
- AstraZeneca